Influence of Uridine Diphosphate‐Glucuronyltransferase 2B7 (UGT2B7) Variants on Postoperative Buprenorphine Analgesia

  title={Influence of Uridine Diphosphate‐Glucuronyltransferase 2B7 (UGT2B7) Variants on Postoperative Buprenorphine Analgesia},
  author={Jos{\'e} A Sastre and Gonzalo M Varela and M{\'o}nica L{\'o}pez and Clemente Muriel and Rogelio Gonz{\'a}lez-Sarmiento},
  journal={Pain Practice},
Genetic factors are known to influence individual differences in pain and sensitivity to analgesics. Different genetic polymorphisms in opioid‐metabolizing enzymes that can affect the analgesic response to opioids have been proposed. This study investigates a possible difference in the response to postoperative buprenorphine analgesia related to the presence of different isoforms (cytosine or thymine substitution at nucleotide 802) of UGT2B7 gene. 
Influence of UGT2B7, CYP3A4, and OPRM1 Gene Polymorphisms on Transdermal Buprenorphine Pain Control in Patients with Critical Lower Limb Ischemia Awaiting Revascularization
Pain control in critical limb ischemia (CLI) varies considerably between individuals and is likely to vary greatly between patients.
A review of the existing literature on buprenorphine pharmacogenomics.
Genotypes in patients with opioid addiction receiving buprenorphine that may result in altered therapeutic dosing and increased rate of relapse are identified, and variations of the pharmacokinetic gene for CYP3A4 showed that the ultrarapid metabolizer phenotype required higher doses of bupenorphine.
Pharmacogenomics of Pain Management: The Impact of Specific Biological Polymorphisms on Drugs and Metabolism
Progress is steadily making progress in the management of pain by being able to identify individual differences in the perception of pain and susceptibility and sensitivity to drugs based on genetic markers, which has a huge potential to increase efficacy and reduce the incidence of iatrogenic drug dependence and addiction.
Molecular monitoring of patient response to painkiller drugs
Common variants in genes involved in pharmacokinetic and pharmacodynamic processes may partially explain the lack of response to painkiller treatment and the occurrence of adverse drug reactions.
Individual postoperative analgesia and gene polymorphisms of CYP 3 A 7 and MDR 1 : an association study
Polymorphisms of CYP3A7 heterozygote and polymorphisms of MDR1 gene could predict high anesthetic sensitivity in gastric cancer patients with high grade of pain, and logistic regression demonstrated that they were risk factors upon age, gender, and surgery status for highAnesthetic sensitivity.
Effects of Single Nucleotide Polymorphisms on Surgical and Postsurgical Opioid Requirements: A Systematic Review and Meta-Analysis
This meta-analysis aims to collate data from studies investigating the effect of SNPs on postoperative and/or intraoperative opioid requirements to build up a personal profile which will predict individual response to drugs, and guide clinicians on the type and dosage of drug to use.
The history and pharmacology of buprenorphine: New advances in cats.
  • T. Clark
  • Biology, Medicine
    Journal of veterinary pharmacology and therapeutics
  • 2022
The history and pharmacology of buprenorphine relative to full opioid agonists, where appropriate, are examined, integrating these insights into advances within feline medicine.
Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option
Although originally designed as an analgesic, buprenorphine has mainly been used for opioid maintenance therapy and only now is increasingly recognized as an effective analgesic with an improved therapeutic index relative to certain potent opioids.


A pharmacogenetic study of uridine diphosphate–glucuronosyltransferase 2B7 in patients receiving morphine
Contribution of the Different UDP-Glucuronosyltransferase (UGT) Isoforms to Buprenorphine and Norbuprenorphine Metabolism and Relationship with the Main UGT Polymorphisms in a Bank of Human Liver Microsomes
It was found that UGT1A1 and UGT2B7 accounted for approximately 10 and 41% of BUP glucuronidation, respectively, and this study represents a functional basis for further clinical pharmacogenetic studies.
Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance.
Although the UGT2B7 polymorphism characterized here is probably not associated with altered enzyme activity, the results highlight the need to consider ethnic variability in assessing the consequences of UGT polymorphisms.
Human UGT2B7 catalyzes morphine glucuronidation.
Cell homogenates and membrane preparations from HK 293 cells expressing UGT2B7 catalyzed the glucuronidation of morphine and other clinically significant opioid agonists, antagonists, and partial agonists.
Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain
Only COMT polymorphisms appear to be predictive of morphine need in postoperative pain therapy by considering COMT, OPRM1, and UGT2B7 genotypes, as well as pharmacokinetic results.
Genetic Predictors of the Clinical Response to Opioid Analgesics
This review uses a candidate gene approach to identify possible pharmacogenetic modulators of opioid therapy, and discusses these modulators together with demonstrated genetic causes for the
Glutathione transferase T1 and M1 genotype polymorphism in the normal population of Shanghai
This study describes the distribution of the two polymorphisms of hGSTT1 and hGGSTM1 in the normal Chinese population of Shanghai and identifies 108 individuals identified to be homozygously deficient for the GSTT1 gene and 107 forThe GSTM1 gene.
The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268).
UGT2B7 seems to be a major human isoform responsible for the glucuronidation of opioids of the morphinan and oripavine class and is capable of catalyzing the glucuridation of both the 3- and 6-hydroxyl moieties on these molecules.
Opiate-induced Analgesia Is Increased and Prolonged in Mice Lacking P-glycoprotein
The results suggest that P-glycoprotein acts to limit the entry of some opiates into the brain and that acute administration of P- glycoprotein inhibitors can increase the sensitivity to these opiates.
The metabolism and excretion of buprenorphine in humans.
The greatest amount of drug and metabolite eliminated in feces occurred at 4 to 6 days following buprenorphine administration at times when there was very little urinary excretion of conjugated bup Renorphine, indicating an enterohepatic circulation of bupRenorphine in humans.